|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pascual D and Borque A: Epidemiology of
kidney cancer. Adv Urol. 2008:7823812008. View Article : Google Scholar
|
|
3
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: A review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
4
|
Reeves DJ and Liu CY: Treatment of
metastatic renal cell carcinoma. Cancer Chemother Pharmacol.
64:11–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chow TF, Youssef YM, Lianidou E, Romaschin
AD, Honey RJ, Stewart R, Pace KT and Yousef GM: Differential
expression profiling of microRNAs and their potential involvement
in renal cell carcinoma pathogenesis. Clin Biochem. 43:150–158.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hadoux J, Vignot S and De La Motte Rouge
T: Renal cell carcinoma: Focus on safety and efficacy of
temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang Y, Dai Y, Yang J, Chen T, Yin Y,
Tang M, Hu C and Zhang L: Microarray analysis of microRNA
expression in renal clear cell carcinoma. Eur J Surg Oncol.
35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naito S, Tomita Y, Rha SY, Uemura H, Oya
M, Song HZ, Zhong LH and Wahid MI: Kidney Cancer Working Group
report. Jpn J Clin Oncol. 40(Suppl 1): i51–i56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Agarwal N, Beard C, Bhayani S,
Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes
GR, et al: National Comprehensive Cancer Network: Kidney cancer. J
Natl Compr Canc Netw. 9:960–977. 2011.PubMed/NCBI
|
|
12
|
Agarwala SS and Case S: Everolimus
(RAD001) in the treatment of advanced renal cell carcinoma: A
review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: Key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
White NM and Yousef GM: MicroRNAs:
Exploring a new dimension in the pathogenesis of kidney cancer. BMC
Med. 8:652010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamasaki T, Seki N, Yamada Y, Yoshino H,
Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M and
Enokida H: Tumor suppressive microRNA 138 contributes to cell
migration and invasion through its targeting of vimentin in renal
cell carcinoma. Int J Oncol. 41:805–817. 2012.PubMed/NCBI
|
|
21
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M
and Enokida H: MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J Urol. 190:1059–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su B, Zhao W, Shi B, Zhang Z, Yu X, Xie F,
Guo Z, Zhang X, Liu J, Shen Q, et al: Let-7d suppresses growth,
metastasis, and tumor macrophage infiltration in renal cell
carcinoma by targeting COL3A1 and CCL7. Mol Cancer. 13:2062014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu D, Pan H, Zhou Y, Zhou J, Fan Y and Qu
P: microRNA-133b downregulation and inhibition of cell
proliferation, migration and invasion by targeting matrix
metallopeptidase-9 in renal cell carcinoma. Mol Med Rep.
9:2491–2498. 2014.PubMed/NCBI
|
|
25
|
Mertens-Talcott SU, Chintharlapalli S, Li
X and Safe S: The oncogenic microRNA-27a targets genes that
regulate specificity protein transcription factors and the G2-M
checkpoint in MDA-MB-231 breast cancer cells. Cancer Res.
67:11001–11011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chintharlapalli S, Papineni S, Abdelrahim
M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S,
Vanderlaag K, Cho SD, et al: Oncogenic microRNA-27a is a target for
anticancer agent methyl
2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer
cells. Int J Cancer. 125:1965–1974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vimalraj S, Miranda PJ, Ramyakrishna B and
Selvamurugan N: Regulation of breast cancer and bone metastasis by
microRNAs. Dis Markers. 35:369–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu T, Tang H, Lang Y, Liu M and Li X:
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by
targeting prohibitin. Cancer Lett. 273:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi D, Li P, Ma L, Zhong D, Chu H, Yan F,
Lv Q, Qin C, Wang W, Wang M, et al: A genetic variant in
pre-miR-27a is associated with a reduced renal cell cancer risk in
a Chinese population. PLoS One. 7:e465662012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reutelingsperger CP: Annexins: Key
regulators of haemostasis, thrombosis, and apoptosis. Thromb
Haemost. 86:413–419. 2001.PubMed/NCBI
|
|
32
|
National Research Council: Guide for the
Care and Use of Laboratory Animals (8th). National Academies Press.
Washington, DC: 2011.
|
|
33
|
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q
and Ma B: MicroRNA-34a inhibits the proliferation and metastasis of
osteosarcoma cells both in vitro and in vivo. PLoS
One. 7(3): e337782012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng S, Calin GA, Croce CM, Coukos G and
Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell
Cycle. 7:2643–2646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Xin S, He Z, Che X, Wang J, Xiao X,
Chen J and Song X: MicroRNA-21 (miR-21) post-transcriptionally
downregulates tumor suppressor PDCD4 and promotes cell
transformation, proliferation, and metastasis in renal cell
carcinoma. Cell Physiol Biochem. 33:1631–1642. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chow TF, Mankaruos M, Scorilas A, Youssef
Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, et
al: The miR-17-92 cluster is over expressed in and has an oncogenic
effect on renal cell carcinoma. J Urol. 183:743–751. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zaman MS, Thamminana S, Shahryari V,
Chiyomaru T, Deng G, Saini S, Majid S, Fukuhara S, Chang I, Arora
S, et al: Inhibition of PTEN gene expression by oncogenic
miR-23b-3p in renal cancer. PLoS One. 7:e502032012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
40
|
Xi Y, Shalgi R, Fodstad O, Pilpel Y and Ju
J: Differentially regulated micro-RNAs and actively translated
messenger RNA transcripts by tumor suppressor p53 in colon cancer.
Clin Cancer Res. 12:2014–2024. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dai Y, Sui W, Lan H, Yan Q, Huang H and
Huang Y: Comprehensive analysis of microRNA expression patterns in
renal biopsies of lupus nephritis patients. Rheumatol Int.
29:749–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fletcher CE, Dart DA, Sita-Lumsden A,
Cheng H, Rennie PS and Bevan CL: Androgen-regulated processing of
the oncomir miR-27a, which targets Prohibitin in prostate cancer.
Hum Mol Genet. 21:3112–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kozaki K, Imoto I, Mogi S, Omura K and
Inazawa J: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer. Cancer Res. 68:2094–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saumet A, Vetter G, Bouttier M,
Portales-Casamar E, Wasserman WW, Maurin T, Mari B, Barbry P,
Vallar L, Friederich E, et al: Transcriptional repression of
microRNA genes by PML-RARA increases expression of key cancer
proteins in acute promyelocytic leukemia. Blood. 113:412–421. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang Z, Liu S, Shi R and Zhao G: miR-27
promotes human gastric cancer cell metastasis by inducing
epithelial-to-mesenchymal transition. Cancer Genet. 204:486–491.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tomas A, Futter CE and Eden ER: EGF
receptor trafficking: Consequences for signaling and cancer. Trends
Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stumm G, Eberwein S, Rostock-Wolf S, Stein
H, Pomer S, Schlegel J and Waldherr R: Concomitant overexpression
of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is
correlated with dedifferentiation and metastasis. Int J Cancer.
69:17–22. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dias F, Teixeira AL, Santos JI, Gomes M,
Nogueira A, Assis J and Medeiros R: Renal cell carcinoma
development and miRNAs: A possible link to the EGFR pathway.
Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shelton JG, Steelman LS, Abrams SL, White
ER, Akula SM, Franklin RA, Bertrand FE, McMahon M and McCubrey JA:
Conditional EGFR promotes cell cycle progression and prevention of
apoptosis in the absence of autocrine cytokines. Cell Cycle.
4:822–830. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lui VW and Grandis JR: EGFR-mediated cell
cycle regulation. Anticancer Res. 22(1A): 1–11. 2002.PubMed/NCBI
|
|
52
|
Liu W, Yin T, Ren J, Li L, Xiao Z, Chen X
and Xie D: Activation of the EGFR/Akt/NF-κB/cyclinD1 survival
signaling pathway in human cholesteatoma epithelium. Eur Arch
Otorhinolaryngol. 271:265–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
